Effects of lamivudine therapy on the glucose metabolism in children with chronic hepatitis B: first year follow-up results.
OBJECTIVE
Although the most common major toxicity of lamivudine has been pancreatitis, there is no report investigating possible impaired pancreatic functions, including glucose intolerance due to lamivudine therapy. The aim of this study was to evaluate the effects of lamivudine on the glucose metabolism in children.


METHODS
Twenty-three children were included: eight patients were treated with lamivudine, others with both lamivudine and interferon-alpha. An oral glucose tolerance test (OGTT) was performed before the treatment, and after 6 and 12 months.


RESULTS
After 6 and 12 months of the treatment four (18.4%) and eight (34.8%) patients had impaired OGTT, respectively. We did not find any relationship between impaired OGTT and age, gender, elevated amylase, abdominal pain and the mode of therapy (P>0.05). While mean glucose value after 2 h was higher than that of baseline, mean insulin concentrations and area under the curve values were not different (P<0.0001, P>0.05, and P>0.05, respectively).


CONCLUSIONS
This is the first report demonstrating that lamivudine may impair the OGTT. Since at least 8.7% of our patients had persistently impaired OGTTs during the first year of the therapy, it may be reasonable to screen children before lamivudine therapy is started.
Ertekin
Vildan
V
Department of Pediatric Gastroenterology, Atatürk University, Faculty of Medicine, Erzurum, Turkey. vildanertekin@hotmail.com
Selimoğlu
Mukadder A
MA
Orbak
Zerrin
Z
D000293:Adolescent; D001786:Blood Glucose / Q000378:metabolism; D002648:Child; D002675:Child, Preschool; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D018149:Glucose Intolerance / Q000097:blood / Q000139:chemically induced*; D005951:Glucose Tolerance Test / Q000379:methods; D019694:Hepatitis B, Chronic / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D007328:Insulin / Q000097:blood; D016898:Interferon-alpha / Q000009:adverse effects; D019259:Lamivudine / Q000009:adverse effects*; D008297:Male; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects*
D001786:Blood Glucose; D007328:Insulin; D016898:Interferon-alpha; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine